BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 21367958)

  • 1. Association of prostate cancer risk Loci with disease aggressiveness and prostate cancer-specific mortality.
    Pomerantz MM; Werner L; Xie W; Regan MM; Lee GS; Sun T; Evan C; Petrozziello G; Nakabayashi M; Oh WK; Kantoff PW; Freedman ML
    Cancer Prev Res (Phila); 2011 May; 4(5):719-28. PubMed ID: 21367958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of 8q24 and 17q risk loci and prostate cancer mortality.
    Penney KL; Salinas CA; Pomerantz M; Schumacher FR; Beckwith CA; Lee GS; Oh WK; Sartor O; Ostrander EA; Kurth T; Ma J; Mucci L; Stanford JL; Kantoff PW; Hunter DJ; Stampfer MJ; Freedman ML
    Clin Cancer Res; 2009 May; 15(9):3223-30. PubMed ID: 19366828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic polymorphism and prostate cancer aggressiveness: a case-only study of 1,536 GWAS and candidate SNPs in African-Americans and European-Americans.
    Bensen JT; Xu Z; Smith GJ; Mohler JL; Fontham ET; Taylor JA
    Prostate; 2013 Jan; 73(1):11-22. PubMed ID: 22549899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prostate cancer susceptibility variant rs2735839 near KLK3 gene is associated with aggressive prostate cancer and can stratify gleason score 7 patients.
    He Y; Gu J; Strom S; Logothetis CJ; Kim J; Wu X
    Clin Cancer Res; 2014 Oct; 20(19):5133-5139. PubMed ID: 25274378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations of prostate cancer risk variants with disease aggressiveness: results of the NCI-SPORE Genetics Working Group analysis of 18,343 cases.
    Helfand BT; Roehl KA; Cooper PR; McGuire BB; Fitzgerald LM; Cancel-Tassin G; Cornu JN; Bauer S; Van Blarigan EL; Chen X; Duggan D; Ostrander EA; Gwo-Shu M; Zhang ZF; Chang SC; Jeong S; Fontham ET; Smith G; Mohler JL; Berndt SI; McDonnell SK; Kittles R; Rybicki BA; Freedman M; Kantoff PW; Pomerantz M; Breyer JP; Smith JR; Rebbeck TR; Mercola D; Isaacs WB; Wiklund F; Cussenot O; Thibodeau SN; Schaid DJ; Cannon-Albright L; Cooney KA; Chanock SJ; Stanford JL; Chan JM; Witte J; Xu J; Bensen JT; Taylor JA; Catalona WJ
    Hum Genet; 2015 Apr; 134(4):439-50. PubMed ID: 25715684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of prostate cancer susceptibility variants on prostate-specific antigen recurrence after radical prostatectomy.
    Huang SP; Huang LC; Ting WC; Chen LM; Chang TY; Lu TL; Lan YH; Liu CC; Yang WH; Lee HZ; Hsieh CJ; Bao BY
    Cancer Epidemiol Biomarkers Prev; 2009 Nov; 18(11):3068-74. PubMed ID: 19900942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients.
    Kader AK; Sun J; Isaacs SD; Wiley KE; Yan G; Kim ST; Fedor H; DeMarzo AM; Epstein JI; Walsh PC; Partin AW; Trock B; Zheng SL; Xu J; Isaacs W
    Prostate; 2009 Aug; 69(11):1195-205. PubMed ID: 19434657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Replication study of 34 common SNPs associated with prostate cancer in the Romanian population.
    Jinga V; Csiki IE; Manolescu A; Iordache P; Mates IN; Radavoi D; Rascu S; Badescu D; Badea P; Mates D
    J Cell Mol Med; 2016 Apr; 20(4):594-600. PubMed ID: 26773531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association study between common variations in some candidate genes and prostate adenocarcinoma predisposition through multi-stage approach in Iranian population.
    Beikzadeh B; Angaji SA; Abolhasani M
    BMC Med Genet; 2020 Apr; 21(1):81. PubMed ID: 32295536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic variants at 1q32.1, 10q11.2 and 19q13.41 are associated with prostate-specific antigen for prostate cancer screening in two Korean population-based cohort studies.
    Kim S; Shin C; Jee SH
    Gene; 2015 Feb; 556(2):199-205. PubMed ID: 25434496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of the HOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomes.
    Kote-Jarai Z; Mikropoulos C; Leongamornlert DA; Dadaev T; Tymrakiewicz M; Saunders EJ; Jones M; Jugurnauth-Little S; Govindasami K; Guy M; Hamdy FC; Donovan JL; Neal DE; Lane JA; Dearnaley D; Wilkinson RA; Sawyer EJ; Morgan A; Antoniou AC; Eeles RA;
    Ann Oncol; 2015 Apr; 26(4):756-761. PubMed ID: 25595936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of prostate cancer risk variants with clinicopathologic characteristics of the disease.
    Xu J; Isaacs SD; Sun J; Li G; Wiley KE; Zhu Y; Hsu FC; Wiklund F; Turner AR; Adams TS; Liu W; Trock BJ; Partin AW; Chang B; Walsh PC; Grönberg H; Isaacs W; Zheng S
    Clin Cancer Res; 2008 Sep; 14(18):5819-24. PubMed ID: 18794092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men.
    Klein RJ; Hallden C; Gupta A; Savage CJ; Dahlin A; Bjartell A; Manjer J; Scardino PT; Ulmert D; Wallström P; Vickers AJ; Lilja H
    Eur Urol; 2012 Mar; 61(3):471-7. PubMed ID: 22101116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of common genetic variations in genes of the sex hormone metabolic pathways on steroid hormone levels and prostate cancer aggressiveness.
    Sun T; Oh WK; Jacobus S; Regan M; Pomerantz M; Freedman ML; Lee GS; Kantoff PW
    Cancer Prev Res (Phila); 2011 Dec; 4(12):2044-50. PubMed ID: 21900597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Replication of prostate cancer risk loci in a Japanese case-control association study.
    Yamada H; Penney KL; Takahashi H; Katoh T; Yamano Y; Yamakado M; Kimura T; Kuruma H; Kamata Y; Egawa S; Freedman ML
    J Natl Cancer Inst; 2009 Oct; 101(19):1330-6. PubMed ID: 19726753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Susceptibility loci associated with prostate cancer progression and mortality.
    Gallagher DJ; Vijai J; Cronin AM; Bhatia J; Vickers AJ; Gaudet MM; Fine S; Reuter V; Scher HI; Halldén C; Dutra-Clarke A; Klein RJ; Scardino PT; Eastham JA; Lilja H; Kirchhoff T; Offit K
    Clin Cancer Res; 2010 May; 16(10):2819-32. PubMed ID: 20460480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of recently identified prostate cancer susceptibility loci in a population-based study: associations with family history and clinical features.
    Fitzgerald LM; Kwon EM; Koopmeiners JS; Salinas CA; Stanford JL; Ostrander EA
    Clin Cancer Res; 2009 May; 15(9):3231-7. PubMed ID: 19366831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genome-wide Scan Identifies Role for AOX1 in Prostate Cancer Survival.
    Li W; Middha M; Bicak M; Sjoberg DD; Vertosick E; Dahlin A; Häggström C; Hallmans G; Rönn AC; Stattin P; Melander O; Ulmert D; Lilja H; Klein RJ
    Eur Urol; 2018 Dec; 74(6):710-719. PubMed ID: 30289108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic variation in prostate-specific antigen-detected prostate cancer and the effect of control selection on genetic association studies.
    Knipe DW; Evans DM; Kemp JP; Eeles R; Easton DF; Kote-Jarai Z; Al Olama AA; Benlloch S; Donovan JL; Hamdy FC; Neal DE; Smith GD; Lathrop M; Martin RM
    Cancer Epidemiol Biomarkers Prev; 2014 Jul; 23(7):1356-1365. PubMed ID: 24753544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate cancer risk alleles are associated with prostate cancer volume and prostate size.
    Reinhardt D; Helfand BT; Cooper PR; Roehl KA; Catalona WJ; Loeb S
    J Urol; 2014 Jun; 191(6):1733-6. PubMed ID: 24345439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.